BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MedPharm Ltd Receives Grant For Insomnia Nasal Spray


4/10/2006 2:26:35 PM

CHICAGO--(BUSINESS WIRE)--April 9, 2006--UK-based topical pharmaceutical development specialist MedPharm Ltd today announced at BIO 2006 in Chicago that it's been awarded a BBSRC* grant to further advance development of a benzodiazepine-based nasal spray for insomnia. The objective is to reduce onset of action to less than 30 minutes through nasal delivery of a reformulated benzodiazepine compared with the 1-2 hours taken by existing tablet and softgel formulations. This grant will be part of a collaboration with OptiNose, a company that is developing a nasal device based on its patented bi-directional delivery technology. The product, which will combine MedPharm's novel formulation with OptiNose's device, will enable quick onset of action by direct delivery of the improved formulation to the target sites in nasal cavity. This route of administration will ensure reproducibility and in turn is expected to lead to improved user compliance. Insomnia affects millions of people across the globe, with a worldwide market estimated to be worth $2.2 billion and growing at 10% per annum.

Read at press release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES